A major pharmaceutical company just received a double dose of good news. But Chief Income Strategist Marc Lichtenfeld still isn't sold. Could this stock be hazardous to your portfolio? Find out in this exclusive interview on CNBC's Talking Numbers.
I wasn’t surprised when the S&P 500 showed the biggest return in 2013 since 1997. Nor am I surprised that the Nasdaq Composite is reaching new highs this year. But I was floored by how few investors seem to be aware that any of this is even happening.